Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

The Fuvid Study: Functional Characterization of Children with Pulmonary Embolism in a Prospective Multicenter Cohort Study

Blood (2024) 144 (Supplement 1): 5555.

https://doi.org/10.1182/blood-2024-202646

Published: 2024

Journal Articles

Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Blood (2024) 144 (Supplement 1): 2633.

https://doi.org/10.1182/blood-2024-212166

Published: 2024

Journal Articles

Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Blood (2024) 144 (Supplement 1): 1257.

https://doi.org/10.1182/blood-2024-212150

Published: 2024

Journal Articles

Use and Outcomes of Secondary Anticoagulation in Patients <21 Years Old Following Completion of a Primary Course of Anticoagulation for Treatment of Acute Provoked VTE: Findings from the Multinational Kids-DOTT Trial

Hope P. Wilson, Marisol Betensky, Alexandra Miller, Ernest K Amankwah, Maua Mosha, John H. Fargo, Arash Mahajerin, Courtney Thornburg, Cristina Tarango, Suchitra Acharya, Christoph Male, Shalu Narang, Sam Schulman, Neil Goldenberg

Blood (2023) 142 (Supplement 1): 1275.

https://doi.org/10.1182/blood-2023-189103

Published: 2023

Journal Articles

Clinical Characteristics, Treatment, and Outcomes of Provoked Acute Cerebral Sinovenous Thrombosis in Patients <21 Years Old: Findings from the Kids-DOTT Multinational Trial

Gary Woods, Alexandra Miller, Maua Mosha, Christoph Male, Anupam Verma, Nicole Kucine, Christine Sabapathy, Kisha A Beg, Sanjay Ahuja, Deepti A. Raybagkar, Kerry Hege, Clara Lo, Rukhmi Bhat, Thomas C. Abshire, Neil Goldenberg

Blood (2023) 142 (Supplement 1): 808.

https://doi.org/10.1182/blood-2023-182167

Published: 2023

Journal Articles

The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results

Gili Kenet, Ampaiwan Chuansumrit, Tadashi Matsushita, Guy Young, Vandana Yadav, Marek Zak, Christoph Male

Blood (2022) 140 (Supplement 1): 2726–2727.

https://doi.org/10.1182/blood-2022-162331

Published: 2022

Journal Articles

Identification By Longread Nanopore Sequencing of a Complex Structural Variant in ITGB3 with a Founder Effect Causing Glanzmann's Thrombasthenia in Two Unrelated Patients

Maria Luisa Lozano, Ana Zamora-Cánovas, Belen De La Morena-Barrio, Cristina Sierra, Christoph Male, Jose Padilla, Maria Eugenia de la Morena-Barrio, Veronica Palma-Barqueros, Ana Sánchez-Fuentes, Agustín Rodriguez-Alen, Ana Marín-Quílez, Nuria Revilla Calvo, Vicente Vicente, Jose Maria Bastida, Javier Corral, Jose Rivera Pozo

Blood (2022) 140 (Supplement 1): 2695–2696.

https://doi.org/10.1182/blood-2022-160181

Published: 2022

Journal Articles

Validating Direct Oral Anticoagulants (DOAC) for Use in Children By the Throm-PED Doac Registry of the International Pediatric Thrombosis Network

Susanne Holzhauer, Christoph Male, Paul Monagle, Mohammadreza Bordbar, Heleen van Ommen, Leslie J. Raffini

Blood (2021) 138 (Supplement 1): 1063.

https://doi.org/10.1182/blood-2021-151005

Published: 2021

Journal Articles

Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation

Guy Young, MD, Anthonie WA. Lensing, MD PhD, Paul Monagle, MBBS, MSc, Christoph Male, MD, Dagmar Kubitza, MD

Blood (2019) 134 (Supplement_1): 164.

https://doi.org/10.1182/blood-2019-124873

Published: 2019

Journal Articles

Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients

Laura L. Swystun, Kenichi Ogiwara, Orla Rawley, Christine Brown, Ilinca Georgescu, Wilma Hopman, Veerle Labarque, Christoph Male, Katharina Thom, Victor S. Blanchette, Manuel D. Carcao, David Lillicrap

Blood (2019) 134 (11): 880–891.

https://doi.org/10.1182/blood.2019000190

Published: 2019

Includes: Supplemental data

Journal Articles

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

H. Marijke van den Berg, Kathelijn Fischer, Manuel Carcao, Hervé Chambost, Gili Kenet, Karin Kurnik, Chris Königs, Christoph Male, Elena Santagostino, Rolf Ljung

Blood (2019) 134 (3): 317–320.

https://doi.org/10.1182/blood.2019000658

Published: 2019

Includes: Supplemental data

Journal Articles

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study

Flora Peyvandi, MD PhD, Paolo Bucciarelli, MD, Carla Valsecchi, BSc, Marco Boscarino, Roberta Palla, PhD, Elena Santagostino, Amal El-Beshlawy, Mohsen Saleh Elalfy, MD, Vijay M. Ramanan, MBBS,MDDM, Peyman Eshghi, MD, Suresh Hanagavadi, MD, Mehran Karimi, MD, Cecil Ross, MD, Mamta V Manglani, MD, Guy Young, Tulika Seth, MDMBBS,FAAP, Shashikant Apte, MD FRCPA, Dinesh M Nayak, MD, Maria Elisa Mancuso, Johnny Mahlangu, Bonanad Santiago, MD, Monica H Cerqueira, MD PhD, Nadia P Ewing, MD, Christoph Male, MD, Tarek Owaidah, MDFRCPA, Veronica Soto Arellano, MD, Suvankar Majumdar, MBCHB, Mindy Simpson, MD, Mathew Thomas, MD, Ezio Zanon, Marilyn J Manco-Johnson, MD, Monica Martinez, MD, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Rogelio Alejandro Paredes-Aguilera, MD, Alessandra N L Prezotti, MD MSc, Klaus Schmitt, MD, Bulent Zulfikar, Prof, Pier Mannuccio Mannucci, MD, Frits Richard Rosendaal, MD

Blood (2018) 132 (Supplement 1): 384.

https://doi.org/10.1182/blood-2018-99-114599

Published: 2018

Journal Articles

Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures

Blood (2018) 132 (Supplement 1): 3774.

https://doi.org/10.1182/blood-2018-99-115979

Published: 2018

Journal Articles

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Blood (2018) 132 (Supplement 1): 2472.

https://doi.org/10.1182/blood-2018-99-114518

Published: 2018

Journal Articles

Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Α- New Insights from the Hemophilia Inhibitor PUP Study (HIPS)

Bagirath Gangadharan, PhD, Birgit Reipert, Fritz Scheiflinger, PhD, Joel Bowen, Elizabeth Donnachie, PhD, Karin Fijn van Draat, Ralph A. Gruppo, MD, Jenny Klintman, MD PhD, Christoph Male, MD, Catherine E. McGuinn, MD, Shannon L. Meeks, MD, Michael Recht, MD PhD, Margaret V. Ragni, MD MPH, Hassan M. Yaish, MD, Amy D. Shapiro, MD, Donald L Yee, MD, Vlad Calin Radulescu, MD, Elena Santagostino, Deborah Brown, MD

Blood (2017) 130 (Supplement 1): 88.

https://doi.org/10.1182/blood.V130.Suppl_1.88.88

Published: 2017

Journal Articles

Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)

Birgit M Reipert, PhD, Bagirath Gangadharan, PhD, Christoph J Hofbauer, PhD, Fritz Scheiflinger, PhD, Joel Bowen, Elizabeth Donnachie, PhD, Karen Fijvandraat, MD, Ralph A. Gruppo, MD, Jenny Klintman, MD PhD, Christoph Male, MD, Catherine E. McGuinn, MD, Shannon L. Meeks, MD, Michael Recht, MD PhD, M V Ragni, MD, Hassan M Yaish, Elena Santagostino, MD PhD, Deborah L Brown, MD

Blood (2016) 128 (22): 328.

https://doi.org/10.1182/blood.V128.22.328.328

Published: 2016

Journal Articles

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Flora Peyvandi, MD PhD, Pier Mannuccio Mannucci, MD, Isabella Garagiola, PhD, Mohsen Elalfy, MD, Amal El-Beshlawy, MD, Madatha V. Ramanan, MD, Peyman Eshghi, MD, Suresh Hanagavadi, Ramabadran Varadarajan, MD, Mehran Karimi, MD, Mamta V. Manglani, MD, Cecil Ross, MD, Guy Young, MD, Tulika Seth, MD, Shashikant Apte, MD FRCPA, Dinesh M. Nayak, MD, Adriana C. Sandoval Gonzales, MD, Elena Santagostino, MD PhD, Maria Elisa Mancuso, MD PhD, Johnny N. Mahlangu, MD, Santiago Bonanad, PhD, Monica Cerqueira, MD, Nadia P. Ewing, MD, Christoph Male, MD MSC, Tarek Owaidah, MD FRCPA, Veronica Soto Arellano, MD, Nathan L. Kobrinsky, MD FRCP, Suvankar Majumdar, MD, Rosario Perez Garrido, MD, Anupam Sachdeva, Mindy Simpson, MD FAAP, Mathew Thomas, Ezio Zanon, MD, ALI Bulent Antmen, Kaan Kavakli, MD, Marilyn Manco-Johnson, MD, Monica Martinez, MD, Esperanza Marzouka, MS, PS, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Angeles Palomo Bravo, MD, Rogelio Paredes Aguilera, MD, Alessandra Nunes Loureiro Prezotti, MD, Schmitt Klaus, MD, Brian M. Wicklund, MD MPH, Bulent Zulfikar, MD, Rosendaal R. Frits, MD PhD

Blood (2015) 126 (23): 5.

https://doi.org/10.1182/blood.V126.23.5.5

Published: 2015

Journal Articles

Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols

Andreas Hanslik, Erwin Kitzmüller, Ulrich S. Tran, Katharina Thom, Hratsch Karapetian, Nicole Prutsch, Jasmin Voitl, Ina Michel-Behnke, Fiona Newall, Christoph Male

Blood (2015) 126 (18): 2091–2097.

https://doi.org/10.1182/blood-2015-06-651661

Published: 2015

Journal Articles

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Christoph J. Hofbauer, Shawn F. J. Whelan, Maria Hirschler, Peter Allacher, Frank M. Horling, John-Philip Lawo, Johannes Oldenburg, Andreas Tiede, Christoph Male, Jerzy Windyga, Andreas Greinacher, Paul N. Knöbl, Gerald Schrenk, Jadranka Koehn, Friedrich Scheiflinger, Birgit M. Reipert

Blood (2015) 125 (7): 1180–1188.

https://doi.org/10.1182/blood-2014-09-598268

Published: 2015

Includes: Supplemental data

Journal Articles

Clearance and Genetic Variability of Von Willebrand Factor Are Major Determinants of the Pharmacokinetic Behavior of Factor VIII Concentrates in the Treatment of Pediatric Hemophilia A

Kenichi Ogiwara, MD PhD, Laura L Swystun, PhD, Ilinca Georgescu, Christine Brown, Angie Tuttle, Shawn Tinlin, Jayne Leggo, Silvia Albánez, MSc, Manuel Carcao, MD MSc, Victor S. Blanchette, MD FRCPC, Christoph Male, MD MSC, Katharina Thom, David Lillicrap, MD

Blood (2014) 124 (21): 473.

https://doi.org/10.1182/blood.V124.21.473.473

Published: 2014

NARROW

The Fuvid Study: Functional Characterization of Children with Pulmonary Embolism in a Prospective Multicenter Cohort Study

Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Use and Outcomes of Secondary Anticoagulation in Patients <21 Years Old Following Completion of a Primary Course of Anticoagulation for Treatment of Acute Provoked VTE: Findings from the Multinational Kids-DOTT Trial

Clinical Characteristics, Treatment, and Outcomes of Provoked Acute Cerebral Sinovenous Thrombosis in Patients <21 Years Old: Findings from the Kids-DOTT Multinational Trial

The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results

Identification By Longread Nanopore Sequencing of a Complex Structural Variant in ITGB3 with a Founder Effect Causing Glanzmann's Thrombasthenia in Two Unrelated Patients

Validating Direct Oral Anticoagulants (DOAC) for Use in Children By the Throm-PED Doac Registry of the International Pediatric Thrombosis Network

Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation

Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study

Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Α- New Insights from the Hemophilia Inhibitor PUP Study (HIPS)

Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Clearance and Genetic Variability of Von Willebrand Factor Are Major Determinants of the Pharmacokinetic Behavior of Factor VIII Concentrates in the Treatment of Pediatric Hemophilia A

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only